A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma
Study of SD-101 in Patients with Metastatic Uveal Melanoma (Eye Cancer) with Liver Disease
Sponsor: TriSalus Life Sciences
Enrolling: Male and Female Patients
IRB Number: AAAT6585
U.S. Govt. ID: NCT04935229
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the best level of dose of SD-101 given by hepatic artery infusion (HAI, a method of putting medication directly into your liver) with using Pressure-Enabled Drug Delivery (PEDD) alone or in combination with nivolumab and/or ipilimumab. Also to find out what effects (both good and bad) SD-101 given by HAI with PEDD has on you and your cancer when given alone or with nivolumab and/or ipilimumab.
Alexander Wei, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with metastatic uveal melanoma (eye cancer) with liver only or liver-dominant disease? Yes No
Have you previously received SD-101? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator